Eye Diseases, Hereditary
Information
- Disease name
- Eye Diseases, Hereditary
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05158296 | Active, not recruiting | Phase 2/Phase 3 | Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) | December 8, 2021 | December 2024 |
| NCT03872479 | Active, not recruiting | Phase 1/Phase 2 | Single Ascending Dose Study in Participants With LCA10 | September 26, 2019 | May 23, 2025 |
| NCT04765345 | Active, not recruiting | Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F | June 8, 2021 | April 1, 2025 | |
| NCT03913143 | Active, not recruiting | Phase 2/Phase 3 | A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) | April 4, 2019 | March 2023 |
| NCT04123626 | Active, not recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene | October 7, 2019 | June 7, 2022 |
| NCT00811512 | Completed | Fundus Changes in the Microphthalmy Eyes | May 2007 | October 2008 | |
| NCT01727973 | Completed | Phase 1/Phase 2 | Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy | October 2012 | November 2013 |
| NCT02946879 | Completed | Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65) | November 2016 | July 2023 | |
| NCT03396042 | Completed | Natural History Study of CEP290-Related Retinal Degeneration | December 17, 2017 | May 6, 2022 | |
| NCT03780257 | Completed | Phase 1/Phase 2 | Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene | March 6, 2019 | October 14, 2021 |
| NCT04945772 | Completed | Phase 2 | Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] | July 13, 2021 | January 18, 2024 |
| NCT06162585 | Enrolling by invitation | Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study | December 8, 2023 | September 2027 | |
| NCT05573984 | Recruiting | Natural History of PRPF31 Mutation-Associated Retinal Dystrophy | July 7, 2022 | April 30, 2027 | |
| NCT05176717 | Terminated | Phase 2/Phase 3 | Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) | December 15, 2021 | August 2, 2022 |
| NCT03913130 | Terminated | Phase 1/Phase 2 | Extension Study to Study PQ-110-001 (NCT03140969) | May 13, 2019 | October 3, 2022 |
| NCT02203682 | Unknown status | Phase 2 | Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy | July 2014 | July 2022 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D015785